You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 162 No. 21, November 25, 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (28)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Nutritional and Metabolic Disorders, Other
 •Obesity
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Effect of Orlistat-Induced Weight Loss, Without Concomitant Hypocaloric Diet, on Cardiovascular Risk Factors and Insulin Sensitivity in Young Obese Chinese Subjects With or Without Type 2 Diabetes

Peter C. Y. Tong, MBBS,PhD,MRCP; Zoe S. K. Lee, PhD; Man-Mei Sea, MPhil; Chun-Chung Chow, MBBS,FRCP; Gary T. C. Ko, MBChB,FRCPI; Wing-Bun Chan, MBChB,MRCP; Wing-Yee So, MBChB,MRCP; Ronald C. W. Ma, MBChB,MRCP; Risa Ozaki, MBChB,MRCP; Jean Woo, MD,FRCP; Clive S. Cockram, MD,FRCP; Juliana C. N. Chan, MD,FRCP

Arch Intern Med. 2002;162:2428-2435.

Background  We examined the weight-losing effect of orlistat treatment on insulin sensitivity and cardiovascular risk factors in a group of severely obese young Chinese patients with or without type 2 diabetes mellitus.

Methods  Obese patients with diabetes (n = 33) and obese nondiabetic patients (n = 27) were given orlistat, 120 mg 3 times daily, without a concomitant hypocaloric diet for 6 months (body mass index [calculated as weight in kilograms divided by the square of height in meter; kg/m2] range, 27.8-47.4). The efficacy measures were (1) insulin sensitivity indices derived from the homeostasis model assessment and a composite measure of whole-body insulin sensitivity index; (2) glycemic control; (3) cardiovascular risk factors, including anthropometry, blood pressure, lipid profiles, and albuminuria; and (4) body composition determined by dual-energy x-ray absorptiometry.

Results  At baseline, patients with diabetes had lower body mass index and percentage of body fat but higher waist-hip ratios and were more insulin resistant. Orlistat therapy reduced body weight, waist and hip circumferences, percentage of total body fat, blood pressure, fasting plasma glucose and lipid levels, albuminuria, and insulin sensitivity indices in both groups (all, P<.05). Despite less weight reduction, we found a greater percentage of reduction from baseline in glycosylated hemoglobin level (-11.6% vs -3.6%; P<.001), fasting plasma glucose level (-18.2% vs -5.0%; P<.001), and systolic blood pressure (-7.1% vs -3.1%; P = .02) in patients with diabetes. Obese subjects without diabetes had greater improvements in triglyceride levels, albuminuria, and the homeostasis model assessment (all, P<.01).

Conclusion  Short-term orlistat treatment without the use of a hypocaloric diet significantly improved insulin sensitivity and cardiovascular risk profiles in severely obese Chinese patients with or without type 2 diabetes.


From the Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. Dr Lee was previously an employee of Roche Hong Kong Ltd, Causeway Bay, Hong Kong.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Current pharmacotherapeutic concepts for the treatment of obesity in adults
Idelevich et al.
Ther Adv Cardiovasc Dis 2009;3:75-90.
ABSTRACT  

Orlistat over the counter
Williams
BMJ 2007;335:1163-1164.
FULL TEXT  

Impact of weight change on albuminuria in the general population
Bello et al.
Nephrol Dial Transplant 2007;22:1619-1627.
ABSTRACT | FULL TEXT  

Genomewide Linkage Analysis of Weight Change in the Framingham Heart Study
Fox et al.
J. Clin. Endocrinol. Metab. 2005;90:3197-3201.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.